Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

作者：Carsten Utoft Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann M. Janssens, Mark‐David Levin, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Münci Yağcı, Loïc Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi S. Srinivasan, Natasha Schuier, Kurt Baeten, Angela J. Howes, Donne Bennett Caces, Arnon Philip Kater · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00452-7 · 被引用次数：149 · 研究领域：Chronic Lymphocytic Leukemia Research、Phagocytosis and Immune Regulation、Lymphoma Diagnosis and Treatment